Duman TT, Ucar Y, Turkoglu ES, Atak Tel BM, Bilgin S, Aktas G. Effects of sodium glucose co-transporter-2 inhibitors and glucagon like peptide-1 receptor agonists in diabetic metabolic dysfunction-associated steatotic liver disease management. World J Diabetes 2026; 17(7): 119285 [DOI: 10.4239/wjd.119285]
Corresponding Author of This Article
Gulali Aktas, Chief Physician, Professor, Department of Internal Medicine, Bolu Abant Izzet Baysal University Hospital, Golkoy, Bolu 14030, Türkiye. draliaktas@yahoo.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
review-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Duman TT, Ucar Y, Turkoglu ES, Atak Tel BM, Bilgin S, Aktas G. Effects of sodium glucose co-transporter-2 inhibitors and glucagon like peptide-1 receptor agonists in diabetic metabolic dysfunction-associated steatotic liver disease management. World J Diabetes 2026; 17(7): 119285 [DOI: 10.4239/wjd.119285]
World J Diabetes. Jul 15, 2026; 17(7): 119285 Published online Jul 15, 2026. doi: 10.4239/wjd.119285
Effects of sodium glucose co-transporter-2 inhibitors and glucagon like peptide-1 receptor agonists in diabetic metabolic dysfunction-associated steatotic liver disease management
Tuba Taslamacioglu Duman, Yagmur Ucar, Elif Sude Turkoglu, Burcin Meryem Atak Tel, Satilmis Bilgin, Gulali Aktas
Tuba Taslamacioglu Duman, Burcin Meryem Atak Tel, Satilmis Bilgin, Gulali Aktas, Department of Internal Medicine, Bolu Abant Izzet Baysal University Hospital, Bolu 14030, Türkiye
Yagmur Ucar, Elif Sude Turkoglu, Faculty of Medicine, Bolu Abant Izzet Baysal University, Bolu 14030, Türkiye
Author contributions: Duman TT and Bilgin S contributed to validation; Duman TT, Ucar Y, Turkoglu ES, Atak Tel BM, and Aktas G contributed to writing-review and editing; Turkoglu ES, Ucar Y, and Bilgin S contributed to writing-original draft; Turkoglu ES, Ucar Y, and Aktas G contributed to conceptualization; Turkoglu ES, Ucar Y, and Atak Tel BM contributed to investigation; Duman TT and Aktas G contributed to supervision; Atak Tel BM contributed to visualization; Bilgin S contributed to the literature search. All authors read and approved the submitted version and approved the final version to publish.
AI contribution statement: ChatGPT was used only for the purpose of language and grammar check in the present work.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
Corresponding author: Gulali Aktas, Chief Physician, Professor, Department of Internal Medicine, Bolu Abant Izzet Baysal University Hospital, Golkoy, Bolu 14030, Türkiye. draliaktas@yahoo.com
Received: January 23, 2026 Revised: February 28, 2026 Accepted: May 19, 2026 Published online: July 15, 2026 Processing time: 167 Days and 14 Hours
Core Tip
Core Tip: Metabolic dysfunction–associated steatotic liver disease is highly prevalent and closely intertwined with type 2 diabetes mellitus, sharing common pathophysiological mechanisms and therapeutic targets. Emerging evidence indicates that sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, beyond their established glycemic benefits, exert favorable effects on body weight, hepatic steatosis, and cardiometabolic risk. This minireview synthesizes current clinical and experimental data on the role of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease, highlighting their mechanisms of action, therapeutic potential, and implications for integrated management of patients with or at risk for type 2 diabetes mellitus.
